Vijaya Diagnostic Centre Limited - Asset Resilience Ratio
Vijaya Diagnostic Centre Limited (VIJAYA) has an Asset Resilience Ratio of 15.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vijaya Diagnostic Centre Limited current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2026)
This chart shows how Vijaya Diagnostic Centre Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Vijaya Diagnostic Centre Limited.
Liquid Assets Composition Over Time
This chart breaks down Vijaya Diagnostic Centre Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Vijaya Diagnostic Centre Limited (VIJAYA) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.28 Billion | 15.15% |
| Total Liquid Assets | Rs2.28 Billion | 15.15% |
Asset Resilience Insights
- Good Liquidity Position: Vijaya Diagnostic Centre Limited maintains a healthy 15.15% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Vijaya Diagnostic Centre Limited Industry Peers by Asset Resilience Ratio
Compare Vijaya Diagnostic Centre Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Lonza Group AG
SW:LONN |
Diagnostics & Research | 3.04% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
SCOPE FLUIDICS SA ZY-10
F:S84 |
Diagnostics & Research | 32.55% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 1.71% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for Vijaya Diagnostic Centre Limited (2019–2026)
The table below shows the annual Asset Resilience Ratio data for Vijaya Diagnostic Centre Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 15.15% | Rs2.28 Billion ≈ $24.70 Million |
Rs15.07 Billion ≈ $162.98 Million |
+0.66pp |
| 2025-03-31 | 14.49% | Rs1.85 Billion ≈ $19.96 Million |
Rs12.74 Billion ≈ $137.74 Million |
+3.39pp |
| 2024-03-31 | 11.10% | Rs1.09 Billion ≈ $11.80 Million |
Rs9.83 Billion ≈ $106.28 Million |
-15.99pp |
| 2023-03-31 | 27.10% | Rs2.31 Billion ≈ $25.01 Million |
Rs8.53 Billion ≈ $92.29 Million |
-2.91pp |
| 2022-03-31 | 30.01% | Rs2.14 Billion ≈ $23.15 Million |
Rs7.13 Billion ≈ $77.16 Million |
-9.35pp |
| 2021-03-31 | 39.36% | Rs2.13 Billion ≈ $23.02 Million |
Rs5.41 Billion ≈ $58.50 Million |
+15.49pp |
| 2020-03-31 | 23.86% | Rs1.15 Billion ≈ $12.45 Million |
Rs4.82 Billion ≈ $52.15 Million |
-3.16pp |
| 2019-03-31 | 27.03% | Rs1.10 Billion ≈ $11.88 Million |
Rs4.06 Billion ≈ $43.95 Million |
-- |
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T ser… Read more